Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRO NASDAQ:AXSM NASDAQ:PCVX NASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$48.31+0.6%$52.22$21.34▼$58.40$3.86B-0.281.42 million shs838,999 shsAXSMAxsome Therapeutics$109.39+4.0%$105.69$75.56▼$139.13$5.46B0.51781,630 shs589,197 shsPCVXVaxcyte$31.55+5.2%$34.23$27.66▼$121.06$4.10B1.211.80 million shs2.64 million shsTVTXTravere Therapeutics$18.05+3.7%$15.53$8.46▼$25.29$1.61B0.741.65 million shs1.65 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics-0.52%-3.09%-6.86%+26.80%+98.55%AXSMAxsome Therapeutics+1.22%+1.58%-3.44%+1.50%+23.92%PCVXVaxcyte+1.11%-11.06%-16.50%+1.97%-61.59%TVTXTravere Therapeutics+0.75%+4.38%+5.71%-17.45%+98.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics4.0961 of 5 stars3.53.00.04.73.30.80.0AXSMAxsome Therapeutics4.8293 of 5 stars4.53.00.04.52.44.20.6PCVXVaxcyte2.0119 of 5 stars3.52.00.00.02.31.70.0TVTXTravere Therapeutics2.0508 of 5 stars3.41.00.00.03.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$81.5768.85% UpsideAXSMAxsome Therapeutics 3.07Buy$178.0062.72% UpsidePCVXVaxcyte 3.09Buy$136.50332.65% UpsideTVTXTravere Therapeutics 2.87Moderate Buy$32.2178.47% UpsideCurrent Analyst Ratings BreakdownLatest TVTX, AXSM, AKRO, and PCVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/10/2025TVTXTravere TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/7/2025TVTXTravere TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform8/7/2025PCVXVaxcyteCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/7/2025TVTXTravere TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$30.00 ➝ $31.008/7/2025TVTXTravere TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$30.00 ➝ $32.008/5/2025AXSMAxsome TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$173.00 ➝ $176.008/5/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$184.00 ➝ $189.008/4/2025AKROAkero TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy8/4/2025AKROAkero TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$76.008/4/2025AXSMAxsome TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$150.007/3/2025AXSMAxsome TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$190.00(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$12.82 per shareN/AAXSMAxsome Therapeutics$495.03M11.03N/AN/A$1.46 per share74.92PCVXVaxcyteN/AN/AN/AN/A$23.66 per shareN/ATVTXTravere Therapeutics$233.18M6.90N/AN/A$0.37 per share48.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%N/AAXSMAxsome Therapeutics-$287.22M-$5.07N/A38.79N/A-49.88%-283.22%-33.06%N/APCVXVaxcyte-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%N/ATVTXTravere Therapeutics-$321.55M-$2.04N/AN/AN/A-50.64%-717.68%-30.69%10/30/2025 (Estimated)Latest TVTX, AXSM, AKRO, and PCVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025AKROAkero Therapeutics-$0.97-$0.86+$0.11-$0.86N/AN/A8/6/2025Q2 2025PCVXVaxcyte-$1.12-$1.22-$0.10-$1.22N/AN/A8/6/2025Q2 2025TVTXTravere Therapeutics-$0.28-$0.14+$0.14-$0.14$100.18 million$94.84 million8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 million5/14/2025Q1 2025PCVXVaxcyte-$1.02-$1.04-$0.02-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0212.6616.80AXSMAxsome Therapeutics1.661.571.51PCVXVaxcyteN/A11.1111.11TVTXTravere Therapeutics9.502.001.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/AAXSMAxsome Therapeutics81.49%PCVXVaxcyte96.78%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%AXSMAxsome Therapeutics22.40%PCVXVaxcyte3.10%TVTXTravere Therapeutics4.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.99 million74.08 millionOptionableAXSMAxsome Therapeutics38049.90 million38.72 millionOptionablePCVXVaxcyte160129.82 million125.80 millionOptionableTVTXTravere Therapeutics46089.14 million85.52 millionOptionableTVTX, AXSM, AKRO, and PCVX HeadlinesRecent News About These CompaniesConnor Clark & Lunn Investment Management Ltd. Boosts Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)August 13 at 4:26 AM | marketbeat.comTVTX FY2025 EPS Forecast Boosted by Cantor FitzgeraldAugust 12 at 3:02 AM | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by AnalystsAugust 12 at 2:16 AM | marketbeat.comCantor Fitzgerald Issues Positive Outlook for TVTX EarningsAugust 11 at 2:31 AM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Price Target Raised to $31.00August 10 at 2:55 AM | americanbankingnews.comWedbush Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) StockAugust 10 at 2:55 AM | americanbankingnews.comTravere Therapeutics price target raised to $32 from $30 at WedbushAugust 8, 2025 | finance.yahoo.comTravere Therapeutics (NASDAQ:TVTX) Given New $31.00 Price Target at ScotiabankAugust 8, 2025 | marketbeat.comWedbush Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $32.00August 8, 2025 | marketbeat.comTravere Therapeutics shares rise as Q2 results top expectationsAugust 7, 2025 | investing.comTravere Therapeutics Reports Strong Q2 2025 GrowthAugust 7, 2025 | msn.comTravere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comTravere Therapeutics, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 6, 2025 | seekingalpha.comHere's What Key Metrics Tell Us About Travere (TVTX) Q2 EarningsAugust 6, 2025 | zacks.comTravere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue EstimatesAugust 6, 2025 | zacks.comEarnings Preview: Travere TherapeuticsAugust 5, 2025 | benzinga.comXTX Topco Ltd Has $935,000 Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)August 4, 2025 | marketbeat.comShort Interest in Travere Therapeutics, Inc. (NASDAQ:TVTX) Rises By 857,233.3%August 3, 2025 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Short Interest UpdateAugust 2, 2025 | marketbeat.comTravere Therapeutics (TVTX) Expected to Announce Earnings on ThursdayJuly 31, 2025 | marketbeat.comTravere Therapeutics to Report Second Quarter 2025 Financial ResultsJuly 30, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTVTX, AXSM, AKRO, and PCVX Company DescriptionsAkero Therapeutics NASDAQ:AKRO$48.31 +0.28 (+0.58%) Closing price 04:00 PM EasternExtended Trading$48.15 -0.16 (-0.33%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Axsome Therapeutics NASDAQ:AXSM$109.39 +4.16 (+3.95%) Closing price 04:00 PM EasternExtended Trading$108.23 -1.16 (-1.06%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Vaxcyte NASDAQ:PCVX$31.55 +1.55 (+5.17%) Closing price 04:00 PM EasternExtended Trading$32.12 +0.57 (+1.79%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Travere Therapeutics NASDAQ:TVTX$18.05 +0.64 (+3.68%) Closing price 04:00 PM EasternExtended Trading$18.06 +0.01 (+0.06%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests 5 Stocks Insiders Are Selling That Analysts Say Buy CoreWeave Pulls Back Into a Screaming Buy Rocket Lab Scores Analyst Upgrades, Finalizes Geost Takeover Why BigBear.ai Stock's Dip on Earnings Can Be an Opportunity Catalysts Align: Archer Beats Estimates, Delivers Aircraft to UAE Intel's White House Reset: From Political Storm to a Clearer Sky On Holdings: Correction Is Over, the Sprint to Highs Is On Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.